In NSCLC, tumor-derived TGF-β significantly enhances CD39 and CD73 expression on MDSCs, which subsequently suppress T cell and NK cell activity while shielding tumor cells from chemotherapy-induced cytotoxicity through the actions of CD39 and CD73 [23]. The gene discussed is ENTPD1; the disease is non-small cell lung carcinoma.